Source: Eur Respir J, 51 (3) 1702508; 10.1183/13993003.02508-2017
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Catharina C. Moor, Mirjam J.G. van Manen, Nelleke C. Tak, Esther van Noort, Marlies S. Wijsenbeek. Development and feasibility of an eHealth tool for idiopathic pulmonary fibrosis. Eur Respir J, 51 (3) 1702508; 10.1183/13993003.02508-2017

Member's Comments

No comment yet.

Related content which might interest you: Validation of a novel prognostic tool for idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 Cost-effectiveness of an online homemonitoring program in idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Evaluation of recently validated non-invasive formula using basic lung functions as a new screening tool for pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Development of a national patient charter for idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 IPFdatabase – A new tool for a correct application of idiopathic pulmonary fibrosis guidelines Source: International Congress 2014 – ILDs 2 Year: 2014 A supportive care decision aid tool for idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines Source: Eur Respir Rev 2014; 23:193-214 Year: 2014 Idiopathic pulmonary fibrosis: approaches to diagnostic Source: Eur Respir J 2002; 20: Suppl. 38, 61s Year: 2002 The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Evolving concepts in the early and accurate diagnosis of idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Evolving concepts in the early and accurate diagnosis of idiopathic pulmonary fibrosis Year: 2010 Potential new biomarkers for idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Proof of concept of a non-invasive screening tool to detect idiopathic pulmonary fibrosis (IPF) in an early stage Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 The epidemiologic features and the patterns of medical resource use in idiopathic pulmonary fibrosis (IPF) in Korea Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Idiopathic pulmonary fibrosis: present understanding and future options Source: Eur Respir Rev 2011; 20: 132-133 Year: 2011 Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017 Year: 2017 Pirfenidone treatment for idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of safety Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009